- Home
- STIM vs PRLD Comparison
STIM vs PRLD Comparison
Compare STIM & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- PRLD
- Stock Information
- Founded
- STIM 2003
- PRLD 2016
- Country
- STIM United States
- PRLD United States
- Employees
- STIM N/A
- PRLD N/A
- Industry
- STIM Medical/Dental Instruments
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- STIM Health Care
- PRLD Health Care
- Exchange
- STIM Nasdaq
- PRLD Nasdaq
- Market Cap
- STIM 83.5M
- PRLD 73.7M
- IPO Year
- STIM 2018
- PRLD 2020
- Fundamental
- Price
- STIM $2.35
- PRLD $1.16
- Analyst Decision
- STIM Buy
- PRLD Strong Buy
- Analyst Count
- STIM 4
- PRLD 2
- Target Price
- STIM $4.67
- PRLD $4.50
- AVG Volume (30 Days)
- STIM 900.5K
- PRLD 628.0K
- Earning Date
- STIM 03-04-2025
- PRLD 02-13-2025
- Dividend Yield
- STIM N/A
- PRLD N/A
- EPS Growth
- STIM N/A
- PRLD N/A
- EPS
- STIM N/A
- PRLD N/A
- Revenue
- STIM $72,711,000.00
- PRLD $3,000,000.00
- Revenue This Year
- STIM $1.97
- PRLD N/A
- Revenue Next Year
- STIM $7.96
- PRLD N/A
- P/E Ratio
- STIM N/A
- PRLD N/A
- Revenue Growth
- STIM 5.03
- PRLD N/A
- 52 Week Low
- STIM $0.52
- PRLD $0.80
- 52 Week High
- STIM $5.07
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- STIM 67.03
- PRLD 47.91
- Support Level
- STIM $2.18
- PRLD $0.98
- Resistance Level
- STIM $2.65
- PRLD $1.31
- Average True Range (ATR)
- STIM 0.29
- PRLD 0.12
- MACD
- STIM 0.04
- PRLD -0.00
- Stochastic Oscillator
- STIM 65.69
- PRLD 25.56
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.